menu

The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies

3 chapters
Play All
1.00 credits
60 Minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.

  • Disclosure of Conflicts of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

    Faculty

    Conflicts of Interest

    Dr. Kuter

    Researcher: Alnylam, BioCryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UC

    Consultant, Advisor, Speaker: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui, Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia), Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen

    Individual publicly traded stocks or stock options: Rubius

    Dr. Cataland

    Consultant, Advisor, Speaker: Sanofi, Takeda

     

    Dr. Broome

    Researcher: Alpine, Novartis, Star

    Consultant, Advisor, Speaker: Alexion, Argenx, Sanofi

    Dr. Neunert

    Researcher: Novartis

    Consultant, Advisor, Speaker: Dova, Janssen, Novartis, Sanofi

  • Target Audience

    The audience for this educational initiative is physicians and advanced practice clinicians who care for people with rare blood disorders.

  • Learning Objectives

    On completion of this activity the learner will be better able to:

    • Describe the recent ISTH evidence-based recommendations for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
    • Explain the diagnosis and management of cold agglutinin disease (CAD) to control anemia and reduce fatigue
    • Summarize the mechanism of action, efficacy and safety, and potential place in therapy for emerging immune thrombocytopenia (ITP) therapies
  • Accreditation and Credit Designation Statements

    Joint Accreditation
    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and CMEology.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Education
    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. 

    Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturers’ product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and CMEology.  For additional information about the accreditation of this activity, please visit https://partnersed.com

  • Supported By

    Supported by an independent educational grant from Sanofi.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.

  • Disclosure of Conflicts of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

    Faculty

    Conflicts of Interest

    Dr. Kuter

    Researcher: Alnylam, BioCryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UC

    Consultant, Advisor, Speaker: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui, Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia), Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen

    Individual publicly traded stocks or stock options: Rubius

    Dr. Cataland

    Consultant, Advisor, Speaker: Sanofi, Takeda

     

    Dr. Broome

    Researcher: Alpine, Novartis, Star

    Consultant, Advisor, Speaker: Alexion, Argenx, Sanofi

    Dr. Neunert

    Researcher: Novartis

    Consultant, Advisor, Speaker: Dova, Janssen, Novartis, Sanofi

  • Target Audience

    The audience for this educational initiative is physicians and advanced practice clinicians who care for people with rare blood disorders.

  • Learning Objectives

    On completion of this activity the learner will be better able to:

    • Describe the recent ISTH evidence-based recommendations for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
    • Explain the diagnosis and management of cold agglutinin disease (CAD) to control anemia and reduce fatigue
    • Summarize the mechanism of action, efficacy and safety, and potential place in therapy for emerging immune thrombocytopenia (ITP) therapies
  • Accreditation and Credit Designation Statements

    Joint Accreditation
    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and CMEology.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Education
    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. 

    Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturers’ product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and CMEology.  For additional information about the accreditation of this activity, please visit https://partnersed.com

  • Supported By

    Supported by an independent educational grant from Sanofi.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Apr 2024